The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patientsí quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Groupís ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
The TogetHER Interview: Partha Basu20/11/2020
The impact of COVID-19 on global cervical cancer prevention efforts has been wide-ranging, with unclear long-term ramifications. The new TogetHER Interview series provides an opportunity for key leaders in global cervical cancer control to discuss current challenges and provide perspective on where the field needs to go from here. This new installment of the TogetHER Interview series features Dr. Partha Basu, Head of the International Agency for Research on Cancerís Screening Group. View the interview.
CanScreen5 Train the Trainers - Africa Region Live session 420/11/2020
Continuation of the CanScreen5 Train the Trainers African course, with participants from 17 African countries. Participants of this training already completed the following e-learning modules: Principle of cancer screening, planning and implementing a cancer screening programme, and quality of cancer screening programme. Today, Dr Sharon Kapambwe, Cancer Assistant Director, Cancer Control, Ministry of Health, Zambia, addressed a key not lecture about the Zambian experience for cervical cancer screening. Learn more about the CanScreen5 platform and the IARC learning platform.
Virtual conference: NCI at London Global Cancer Week 202020/11/2020
This virtual conference is organized by the US National Cancer Institute Center for Global Health (CGH) within the London Global Cancer Week 2020. This webinar will showcase examples of global cancer research partnerships and collaborations from the US National Cancer Institute (NCI) perspective. The session will start with an overview of NCI Center for Global Health (CGH) and NCI global health priorities as laid out by CGH Director Satish Gopal, MD, MPH. The session will also include unique viewpoints on building global cancer research collaborations as outlined by NIH-funded cancer researchers and trainees from different regions of the world. The presentations will highlight aspects of partnership-building to advance global cancer research, lessons learned, and recommendations. Dr Partha Basu, Head of Screening Group, Early Detection & Prevention Section at the International Agency for Research on Cancer will discuss about the role of collaborative research to identify effective and affordable technologies and inform global policies in cancer prevention. View more about this virtual conference and free registration.
New publication: Digital atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment17/11/2020
To mark the official launch by the World Health Organization of the Global Strategy to Accelerate the Elimination of Cervical Cancer, the International Agency for Research on Cancer (IARC) is pleased to announce the launch of a new digital atlas, the Atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment. The objectives of the new atlas are to describe the use of visual inspection of the cervix with acetic acid (VIA) as a primary screening test or as a test to triage women who test positive for oncogenic human papillomavirus (HPV) types, and to explain how application of dilute acetic acid to the cervix can help in determining eligibility for ablative treatment. View the digital atlas, the IARC news, the IARC page about WHO Global Strategy to Accelerate the Elimination of Cervical Cancer.
|Bhatla N., Nessa A., Oswal K., Vashist S., Sebastian P., Basu P. Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. Int J Gynaecol Obstet. 2020 Nov 18.|
|Taghavi K., Rohner E., Basu P., Low N., Rutjes A., Bohlius J. Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. BMC Womens Health. 2020 Nov 16;20(1):253.|
|Kumar S., Khanduri A., Sidibe A., Morgan C., Torode J., Basu P., Bhatla N., Schocken C., Bloem P. Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2020 Nov 13.|